Q-omics provides the consensus-scored SIGLEC30P profile across patient tissues and cancer cell-line models. SIGLEC30P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SIGLEC30P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, SIGLEC30P RNA expression shows 7,172 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, HNSC, and ESCA as cancer lineages where SIGLEC30P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLEC30P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLEC30P survival associations across molecular data types. SIGLEC30P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLEC30P RNA expression–survival associations across cancer types. High SIGLEC30P expression shows unfavorable associations in MESO, KICH, BLCA, KIRP, READ and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SIGLEC30P RNA expression.
This table summarizes SIGLEC30P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SIGLEC30P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLEC30P shows higher tumor expression in HNSC, BRCA, LUSC, STAD and LUAD. The HNSC box plot shows higher SIGLEC30P RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .006).
This table shows molecular features associated with SIGLEC30P in patient tissues and cancer cell lines. In patient samples, SIGLEC30P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
